Project Grant R01ES037601
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $462,501 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, to conduct research on mast cell activation as a common mechanism of pulmonary toxicity from chemical threat agents. The two-year project aims to examine how activation of mast cells contributes to lung inflammation and injury caused by exposure to various...
- This federal Project Grant award for $223,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance scientific understanding of mast cell functions and inflammatory responses. The research will investigate regulatory pathways that limit mast cell activation, with a focus on the role of the ITCH ubiquitin ligase enzyme in controlling inflammation and restoring homeostasis. The project,...
- This federal Project Grant award of $612,328 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to enhance the understanding of mast cell lineage commitment and function. The research aims to determine how the transcription factor MITF maintains mast cell-specific gene expression and suppresses basophil-specific gene expression, as well as evaluate the functional deficiencies of mast...
- This federal Project Grant award from the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $489,008 to Old Dominion University to investigate how enhancing the endocannabinoid signaling system, specifically by inhibiting the enzyme monoacylglycerol lipase (MAGL), could confer protection against lung injury caused by chemical threat agents such as nitrogen mustard and ammonia. The research...
- This $387,116 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of South Florida to investigate the sensory neuronal mechanisms underlying the development of house dust mite-induced airway hyperreactivity, a key characteristic of asthma. The long-term goal is to define the neural mechanisms triggered by house dust mite exposure that lead to the development of airway...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $235,500 to Rutgers, The State University of New Jersey to conduct research on reducing chlorine-induced lung toxicity through the inhibition of macrophage activation. The research aims to develop medical countermeasures to mitigate the severe respiratory complications that can result from exposure to chlorine, a reactive gas that has been used as a chemical warfare...
- This Project Grant award for $744,880.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate how lactate produced by alveolar epithelial type II cells can shift alveolar macrophages towards an anti-inflammatory phenotype, which could enable therapeutic exploitation of this innate protective mechanism in acute lung injury and acute respiratory distress syndrome. The...
- The U.S. Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,993,748 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the Trustees of the Colorado School of Mines. The 4-year grant, commencing on September 1, 2025, will support research to investigate how polymer brush-coated cell culture substrates can be used to understand and direct macrophage polarization, which is critical for wound healing, inflammation, and...
- This $428,220 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Colorado-Denver to provide "Innovative Insights into Pulmonary Hypertension Progression: Unraveling the Role of Localized Small Extracellular Vesicles." The research, conducted from December 1, 2024 through November 30, 2026, aims to advance the scientific understanding of pulmonary hypertension and...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to define the mechanisms through which early life adversity and biological sex developmentally heighten the pro-inflammatory phenotype of mast cells by modulating their cholesterol metabolism. The $101,577 award to Michigan State University, granted on January 1, 2025, aims to further the understanding of...
This federal Project Grant award, provided by the Department of Health and Human Services National Institutes of Health under the Trans-NIH Research Support program (CFDA 93.310), funds research to investigate mast cell activation as a common mechanism of pulmonary toxicity caused by chemical threat agents. The $1,395,741 award to the University of Colorado-Denver, effective September 1, 2025 through August 31, 2028, will support two specific aims. The research aims to confirm the in vivo contribution of mast cells to pulmonary injury and inflammation resulting from exposure to the chemical threat agents chloropicrin and formaldehyde. The overall hypothesis is that mast cell activation is a common initiating step in the immune response to multiple classes of chemical threat agents in the lung. The findings could identify shared mechanisms and therapeutic targets for mitigating pulmonary toxicity from these hazardous chemicals.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.4m | 8/29/25 |